메뉴 건너뛰기




Volumn 22, Issue 2, 2014, Pages 90-95

Long-term treatment with golimumab for severe uveitis

Author keywords

Golimumab; HLA B27; JIA; TNF alpha blockers; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE ACETATE; RITUXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

EID: 84897546532     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.844265     Document Type: Article
Times cited : (79)

References (18)
  • 1
    • 33847025627 scopus 로고    scopus 로고
    • Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-Term follow-up study
    • Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-Term follow-up study. Arthritis Rheum. 2007;56:647-657
    • (2007) Arthritis Rheum , vol.56 , pp. 647-657
    • Saurenmann, R.K.1    Levin, A.V.2    Feldman, B.M.3
  • 2
    • 0031793309 scopus 로고    scopus 로고
    • Outcomes in anterior uveitis associated with the HLAB27 haplotype
    • Power WJ, Rodriguez A, Peroza-Seres M, Foster CS. Outcomes in anterior uveitis associated with the HLAB27 haplotype. Ophthalmology. 1998;105;1646-1651
    • (1998) Ophthalmology , vol.105 , pp. 1646-1651
    • Power, W.J.1    Rodriguez, A.2    Peroza-Seres, M.3    Foster, C.S.4
  • 3
    • 80855138673 scopus 로고    scopus 로고
    • Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases
    • Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35-39
    • (2011) Autoimmun Rev , vol.11 , pp. 35-39
    • Miserocchi, E.1    Pontikaki, I.2    Modorati, G.3
  • 4
    • 22844450941 scopus 로고    scopus 로고
    • A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes
    • Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005; 123:903-912
    • (2005) Arch Ophthalmol , vol.123 , pp. 903-912
    • Suhler, E.B.1    Smith, J.R.2    Wertheim, M.S.3
  • 5
    • 33747856804 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis
    • Saurenmann RK, Levin AV, Rose JB, et al. Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982-989
    • (2006) Rheumatology , vol.45 , pp. 982-989
    • Saurenmann, R.K.1    Levin, A.V.2    Rose, J.B.3
  • 6
    • 34248633648 scopus 로고    scopus 로고
    • Tumor necrosis factor-Alpha blocker in treatment of juvenile idiopathic arthritis-Associated uveitis refractory to second-line agents: Results of a multinational survey
    • Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-Alpha blocker in treatment of juvenile idiopathic arthritis-Associated uveitis refractory to second-line agents: Results of a multinational survey. J Rheumatol. 2007;34:1146-1150
    • (2007) J Rheumatol , vol.34 , pp. 1146-1150
    • Foeldvari, I.1    Nielsen, S.2    Kummerle-Deschner, J.3
  • 7
    • 66149093549 scopus 로고    scopus 로고
    • Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study
    • Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68: 696-701
    • (2009) Ann Rheum Dis , vol.68 , pp. 696-701
    • Rudwaleit, M.1    Rodevand, E.2    Holck, P.3
  • 8
    • 47949101475 scopus 로고    scopus 로고
    • Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric longterm prospective study of 163 patients
    • Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric longterm prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145-1152
    • (2008) Ann Rheum Dis , vol.67 , pp. 1145-1152
    • Gerloni, V.1    Pontikaki, I.2    Gattinara, M.3    Fantini, F.4
  • 9
    • 77953701867 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite methotrextae therapy: 52-week results of the goforward study
    • Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrextae therapy: 52-week results of the GOFORWARD study. Ann Rheum Dis. 2010;69:1129-1135
    • (2010) Ann Rheum Dis , vol.69 , pp. 1129-1135
    • Keystone, E.1    Genovese, M.C.2    Klareskog, L.3
  • 10
    • 67650379733 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
    • Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374:210-221
    • (2009) Lancet , vol.374 , pp. 210-221
    • Smolen, J.S.1    Kay, J.2    Doyle, M.K.3
  • 11
    • 68049099274 scopus 로고    scopus 로고
    • Golimumab, a human anti-Tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-nai?ve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
    • Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-Tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-nai?ve patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272-2283
    • (2009) Arthritis Rheum , vol.60 , pp. 2272-2283
    • Emery, P.1    Fleischmann, R.M.2    Moreland, L.W.3
  • 12
    • 10744230484 scopus 로고    scopus 로고
    • International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, edmonton, 2001
    • Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-392
    • (2004) J Rheumatol , vol.31 , pp. 390-392
    • Petty, R.E.1    Southwood, T.R.2    Manners, P.3
  • 13
    • 24044463655 scopus 로고    scopus 로고
    • Standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop
    • The Standardization of Uveitis Nomenclature (SUN) working group
    • The Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop. Am J Ophthalmol. 2005;140:509-516
    • (2005) Am J Ophthalmol , vol.140 , pp. 509-516
  • 15
    • 84869836247 scopus 로고    scopus 로고
    • Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis
    • William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis. J Ophthal Inflamm Infect. 2012;2:231-233
    • (2012) J Ophthal Inflamm Infect , vol.2 , pp. 231-233
    • William, M.1    Faez, S.2    Papaliodis, G.N.3    Lobo, A.M.4
  • 16
    • 84876004363 scopus 로고    scopus 로고
    • Behçet disease-Associated uveitis successfully treated with golimumab
    • Mesquida M, Hernandez MV, Llorenc V, et al. Behçet disease-Associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2012;21:160-162
    • (2012) Ocul Immunol Inflamm , vol.21 , pp. 160-162
    • Mesquida, M.1    Hernandez, M.V.2    Llorenc, V.3
  • 18
    • 33846239331 scopus 로고    scopus 로고
    • Outcomes after switching from one anti-Tumor necrosis factor alpha agent to a second anti-Tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    • Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-Tumor necrosis factor alpha agent to a second anti-Tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20
    • (2007) Arthritis Rheum , vol.56 , pp. 13-20
    • Hyrich, K.L.1    Lunt, M.2    Watson, K.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.